Alnylam Pharmaceuticals, Inc. has conducted research on siRNA drugs targeting GPR75 mRNA for the prevention and treatment of weight disorders, such as obesity and related diseases.290. The gene discussed is GPR75; the disease is obesity due to melanocortin 4 receptor deficiency.